Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jul;22(1):746.
doi: 10.3892/etm.2021.10178. Epub 2021 May 11.

Nephrogenic diabetes insipidus in children (Review)

Carmen Duicu  1 , Ana Maria Pitea  1 , Oana Maria Săsăran  2 , Iulia Cozea  1 , Lidia Man  1 , Claudia Bănescu  3
Affiliations
Review

Nephrogenic diabetes insipidus in children (Review)

Carmen Duicu et al. Exp Ther Med. 2021 Jul.

Abstract

Nephrogenic diabetes insipidus (NDI) is characterized by impaired urinary concentrating ability, despite normal or elevated plasma concentrations of the antidiuretic hormone, arginine vasopressin (AVP). NDI can be inherited or acquired. NDI can result from genetic abnormalities, such as mutations in the vasopressin V2 receptor (AVPR2) or the aquaporin-2 (AQP2) water channel, or acquired causes, such as chronic lithium therapy. Congenital NDI is a rare condition. Mutations in AVPR2 are responsible for approximately 90% of patients with congenital NDI, and they have an X-linked pattern of inheritance. In approximately 10% of patients, congenital NDI has an autosomal recessive or dominant pattern of inheritance with mutations in the AQP2 gene. In 2% of cases, the genetic cause is unknown. The main symptoms at presentation include growth retardation, vomiting or feeding concerns, polyuria plus polydipsia, and dehydration. Without treatment, most patients fail to grow normally, and present with associated constipation, urological complication, megacystis, trabeculated bladder, hydroureter, hydronephrosis, and mental retardation. Treatment of NDI consist of sufficient water intake, low-sodium diet, diuretic thiazide, sometimes in combination with a cyclooxygenase (COX) inhibitor (indomethacin) or nonsteroidal anti-inflammatory drugs (NSAIDs), or hydrochlorothiazide in combination with amiloride. Some authors note a generally favorable long-term outcome and an apparent loss of efficacy of medical treatment during school age.

Keywords: children; inherited; nephrogen; nephrogenic diabetes insipidus; polydipsia; polyuria.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there are no commercial or financial relationships that could be construed as potential competing interests.

Similar articles

See all similar articles

Cited by

References

    1. Caletti MG, Balestracci A, Di Pinto D. Pre- and post-treatment urinary tract findings in children with nephrogenic diabetes insipidus. Pediatr Nephrol. 2014;29:487–490. doi: 10.1007/s00467-013-2689-z. - DOI - PubMed
    1. Bichet DG. Treatment of nephrogenic diabetes insipidus. UpToDate. https://www.uptodate.com/contents/treatment-of-nephrogenic-diabetes-insi..., 2017. Accessed June 14, 2019.
    1. Moeller HB, Rittig S, Fenton RA. Nephrogenic diabetes insipidus: Essential insights into the molecular background and potential therapies for treatment. Endocr Rev. 2013;34:278–301. doi: 10.1210/er.2012-1044. - DOI - PMC - PubMed
    1. Mishra G, Chandrashekhar SR. Management of diabetes insipidus in children. Indian J Endocrinol Metab. 2011;15 (Suppl 3):S180–S187. doi: 10.4103/2230-8210.84858. - DOI - PMC - PubMed
    1. Ranieri M, Di Mise A, Tamma G, Valenti G. Vasopressin-aquaporin-2 pathway: Recent advances in understanding water balance disorders. F1000Res. 2019;8(F1000) doi: 10.12688/f1000research.16654.1. - DOI - PMC - PubMed

Grants and funding

Funding: No funding was received.